17403-03-1

Usage

Uses

Used in Neurotoxicity Research:
Norharmane is utilized as a neurotoxicant in scientific studies, helping researchers understand its effects on the nervous system and potentially contributing to the development of treatments for neurological disorders.
Used in Cancer Biology Research:
In the field of oncology, norharmane is employed as a subject of investigation for its potential role in cancer biology. Its study may lead to insights into the mechanisms of cancer progression and the identification of novel therapeutic targets.
Used in Drug Development:
Norharmane is considered in the development of new drugs due to its pharmacological properties. Its unique structure may offer opportunities for the creation of innovative therapeutic agents.
Used as a Fluorescent Probe in Biochemical and Medical Research:
In biochemical and medical research, norharmane serves as a fluorescent probe, enabling the visualization and study of biological processes and structures, which can be crucial for advancing our understanding of various diseases and conditions.
Used in Organic Chemistry:
In the realm of organic chemistry, norharmane is of interest for its structural characteristics, which may inspire the synthesis of new compounds with potential applications in various industries.

InChI:InChI=1/C14H16N2/c1-16-8-6-11(7-9-16)13-10-15-14-5-3-2-4-12(13)14/h2-6,10,15H,7-9H2,1H3

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 120-72-9 indole 

Downstream Products

• 17403-07-5 3-(1-methylpiperidin-4-yl)-1H-indole 
• 82420-24-4 3-Methyl-6-phenyl-1,2,3,4,4a,6,7,11c-octahydropyrido<3,4-b>pyrano<3,4-b>indole Hydrochloride 
• 134745-18-9 3-methyl-1,2,3,4,5,6,7,8-octahydro-6-phenylpyrido<3,4-c>pyrrolo<3,4-a>carbazol-5,7-dione 

Relevant academic research and scientific papers

BENZYL-SUBSTITUTED TETRACYCLIC HETEROCYCLIC COMPOUNDS

The present invention pertains to Benzyl-substituted tetracyclic heterocyclic compounds of formula (I), as well as the resulting pharmaceutical compositions, and their use in the treatment or prophylaxis of diseases alleviated by inhibition of type 5 phosphodiesterases. Furthermore, the present invention pertains to the methods of manufacturing these Benzyl -substituted tetracyclic heterocyclic compounds.

PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY

Described herein are indole compounds with affinity for the 5-HT6 receptor, which have general formula (I) wherein, R is selected from the group consisting of H and C1-4alkyl; R is selected from the group consisting of H, C1-4alkyl and benzyl; -----

Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors

A series of indole tetrahydropyridine and indole cyclohexenylamines was prepared, and their binding affinities at the human serotonin transporter (SERT) were determined. In particular, a nitrile substituent at the C5 position of the indole ring gave poten

N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists

The development of a series of N1-sulfonyl-3-(1,2,3,6- tetrahydropyridin-4-yl)indole 5-HT6 antagonists is described. Two analogs, 15g and 15y, had 0.4 and 3.0 nM affinity, and antagonized the production of adenylate cyclase at sub-nanomolar concentrations. A series of N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)indole derivatives was designed and synthesized. These compounds were shown to have high affinity for the 5-HT6 receptor. Two analogs, 4-[3-(1,2,3,6-tetrahydropyridin- 4-yl)-1H-indole-1-sulfonyl]-phenylamine 15g and 4-[3-(1,2,3,6-tetrahydropyridin- 4-yl)-5-methoxy-1H-indole-1-sulfonyl]-phenylamine 15y, had 0.4 and 3.0 nM affinity, respectively, and antagonized the production of adenylate cyclase at sub-nanomolar concentrations.

Piperidine-indole compounds having 5-HT6 affinity

Described herein are compounds with affinity for the 5-HT6 receptor, which have the general formula: wherein: R1 is selected from the group consisting of H and C1-4alkyl; R2 is selected from the group consisting of H, C1-4alkyl and benzyl; - - - represents a single or double bond; R3 is selected from the group consisting of COR5 and SO2R5; R4a is selected from the group consisting of H, OH, halo, C1-4alkyl and C1-4alkoxy; R4b is selected from the group consisting of H, hydroxy, halo, C3-7cycloalkyloxy, C1-4alkoxy, C1-4alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl; R4c is selected from the group consisting of H, OH, halo, C1-4alkyl and C1-4alkoxy; R4d is selected from the group consisting of H, OH, halo, C1-4alkyl and C1-4alkoxy; and R5 is selected from the group consisting of phenyl, pyridyl, thienyl, quinolinyl and naphthyl which are optionally substituted with 1-4 substituents selected from C1-4alkoxy, C1-4alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C1-4alkylcarbonyl, C1-4alkoxycarbonyl and C1-4alkylS-. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT6 receptor is implicated, such as schizophrenia.

Treating psychic disorders with tetrahydropyridin-4-yl-1H-indoles

Novel antidepressant, antiemetic and neuroleptic compositions containing as the active ingredient at least one compound of the formula STR1 wherein R is selected from the group consisting of hydrogen and methoxy, R1 and R2 are individually selected from the group consisting of hydrogen and methyl and their non-toxic, pharmaceutically acceptable acid addition salts and a novel method of treating psychic disorders in warm-blooded animals.